We have previously demonstrated that human neutrophil cathepsin G is a strong platelet agonist that binds to a specific receptor. This work describes the effect of neutrophil elastase on cathepsin G-induced platelet responses. While platelets were not activated by high concentrations of neutrophil elastase by itself, elastase enhanced aggregation, secretion and calcium mobilization induced by low concentrations of cathepsin G. Platelet aggregation and secretion were potentiated in a concentration-dependent manner by neutrophil elastase with maximal responses observable at 200 nM. Enhancement was observed when elastase was preincubated with platelets for time intervals of 10–60 s prior to addition of a low concentration of cathepsin G and required catalytically-active elastase since phenylmethanesulphonyl fluoride-inhibited enzyme failed to potentiate cell activation. Neutrophil elastase potentiation of platelet responses induced by low concentrations of cathepsin G was markedly inhibited by creatine phosphate/creatine phosphokinase and/or indomethacin, indicating that the synergism between elastase and cathepsin G required the participation of ADP and thromboxane A2. On the other hand, platelet responses were not attenuated by the PAF antagonist BN 52021, signifying that PAF-acether did not play a role in elastase potentiation. At higher concentrations porcine pancreatic elastase exhibits similar effects to neutrophil elastase, demonstrating that the effect of elastase was not unique to the neutrophil protease. While neutrophil elastase failed to alter the ability of cathepsin G to hydrolyze a synthetic chromogenic substrate, preincubation of platelets with elastase increased the apparent affinity of cathepsin G binding to platelets. In contrast to their effect on cathepsin G-induced platelet responses, neither neutrophil nor pancreatic elasatse potentiated aggregation or dense granule release initiated by ADP, PAF-acether, arachidonic acid or U46619, a thromboxane A2 mimetic. Moreover, unlike its effect on cathepsin G, neutrophil elastase inhibited thrombin-induced responses. The current observations demonstrate that elastase can potentiate platelet responses mediated by low concentrations of cathepsin G, suggesting that both enzymes may function synergistically to activate platelets under conditions where neutrophil degranulation occurs.
REFERENCES
1
Janoff A.
Elastase in tissue injury. Annu Rev Med 1985; 36: 207-216
2
Egbring R,
Schmidt W,
Fuchs G,
Havemann K.
Demonstration of granulocytic proteinases in plasma of patients with acute leukemia and septicemia with blood coagulation defects. Blood 1977; 49: 219-231
3
Bykowska K,
Kaczanowska J,
Karpowicz M,
Stachurska J,
Kopeac M.
Effect of neutral proteases from blood leukocytes on human platelets. Thromb Haemostas 1983; 50: 768-772
4
Bykowska K,
Kaczanowska J,
Karpowicz M,
Lopaciuk S,
Kopec M.
Alterations of blood platelet function induced by neutral proteases from human leukocytes. Thromb Res 1985; 38: 535-546
5
Kornecki E,
Ehrlich YH,
DeMars DD,
Lenox RH.
Exposure of fibrinogen receptors in human platelets by surface proteolysis with elastase. J Clin Invest 1986; 77: 750-756
6
Brower MS,
Levin RI,
Garry K.
Human neutrophil elastase modulates platelet function by limited proteolysis of membrane glycoproteins. J Clin Invest 1985; 75: 657-666
7
Wicki A,
Clemetson KJ.
Effects of leukocyte elastase and other proteases on platelet response to von Willebrand Factor. Eur J Biochem 1985; 153: 01-11
8
Chignard M,
Selak MA,
Smith JB.
Direct evidence for the existence of a neutrophil-derived platelet activator (neutrophilin). Proc Natl Acad Sci 1986; 83: 8609-8613
12
Grynkiewicz G,
Peonie M,
Tsien RY.
A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem. 1985; 260: 3440-3450
15
Nakajima K,
Powers J,
Ashe BM,
Zimmerman M.
Mapping the extended substrate binding site of cathepsin G and human leukocyte elastase. J Biol Chem 1979; 254: 4027-4031
17
Coller BS,
Peerschke EI,
Scudder LE,
Sullivan CA.
A murine monoclonal antibody that completely blocks the binding site of fibrinogen to platelets produces a thrombestenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 1983; 72: 325-338
18
Plow EF,
Marguierie G,
Ginsberg M.
Fibrinogen, fibrinogen receptors, and the peptides that inhibit these interactions. Biochem Pharmacol 1987; 36: 4035-4040
20
Salvesen G,
Farley D,
Shuman J,
Przybyla A,
Reilly C,
Travis J.
Molecular cloning of human cathepsin G: structural similarity to mast cell and cytotoxic T lymphocyte proteinases. Biochemistry 1987; 26: 2289-2293
22
Starkey PM,
Barrett AJ.
Neutral proteases of human spleen. Purification and criteria for homogeneity of elastase and cathepsin G. Biochem J 1976; 155: 255-263
23
Roughley PM,
Barrett AJ.
The degradation of cartilage proteoglycans by tissue proteinases. Proteoglycan structure and its susceptibility to proteolysis. Biochem J 1977; 167: 629-637
25
Laurell CB.
Variation of the alpha-1-antitrypsin level of plasma. In: Pulmonary Emphysema and Proteolysis.
Mittman C.
(ed)
Academic Press, New York: 1972. pp 161-166
28
Tanaka T,
Minematsu Y,
Reilly CF,
Travis J,
Powers JC.
Human leukocyte cathepsin G. Subsite mapping with 4-nitroanilides, chemical modification and effect of possible cofactors. Biochemistry 1985; 24: 2040-2047
29
Senior RM,
Campbell EJ.
Cathepsin G in human mononuclear phagocytes: comparisons between monocytes and U937 monocyte-like cells. J Immunol 1984; 132: 2547-2551